Skip to main content

Table 2 Demographic, clinical, histological, molecular and treatment characteristics of patients and analysis of groups homogeneity (test Pearson Khi2)

From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer

Characteristic

Group A [n = 110] No (%)

Group B [n = 134] No (%)

p value

Age

   <40

31 (28.2%)

23 (17.2%)

0.039

   ≥40

79 (71.8%)

111 (82.8%)

 

Menopausal status

   No

75 (72.8%)

77 (62.1%)

0.087

   Yes

28 (27.2%)

47 (37.9%)

 

Side

   Right

48 (43.6%)

71 (53%)

0.146

   Left

62 (56.4%)

63 (47%)

 

Surgery

   Mastectomy (Patey or Halsted)

89 (80.9%)

116 (86.6%)

0.23

   Conservative

21 (19.1%)

18 (13.4%)

 

Histology

   DIC

99 (94,3%)

120 (90,9%)

0.33

   LIC

6 (5.7%)

12 (9.1%)

 

SBR

   I

6 (5.7%)

11 (8.5%)

0.567

   II

69 (65.1%)

87 (66.9%)

 

   III

31 (29.2%)

32 (24.6%)

 

Hormonal receptors

ER

   Positive

77 (72%)

97 (73.5%)

0.793

   Negative

30 (28%)

35 (26.5%)

 

PR

   Positive

61 (57.5%)

82 (62.1%)

0.474

   Negative

45 (42.5%)

50 (37.9%)

 

Tumour

   pT1

16 (14.7%)

19 (14.5%)

0.732

   pT2

62 (56.9%)

76 (58%)

 

   pT3

28 (25.7%)

29 (22.1%)

 

   pT4

3 (2.8%)

7 (5.3%)

 

pN, axillary

   pN0

20 (18.2%)

40 (29.9%)

0.001

   pN1

30 (27.3%)

42 (31.3%)

 

   pN2

31 (28.2%)

42 (31.3%)

 

   pN3

29 (26.4%)

10 (7.5%)

 

Breast/thoracic wall irradiation

   Yes

109 (99.1%)

124 (92.5%)

0.014

   No

1 (0.9%)

10 (7.5%)

 

Prophylactic supraclavicular fossa radiotherapy

   Yes

104 (94.5%)

127 (94.8%)

0.936

   No

6 (5.5%)

7 (5.2%)

 

Internal mammary radiotherapy

   Yes

105 (95.5%)

128 (95.5%)

0.98

   No

5 (4.5%)

6 (4.5%)

 

Axillary radiotherapy

   Yes

18 (16.4%)

31 (23.1%)

0.189

   No

92 (83.6%)

103 (76.9%)

 
  1. SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor